BE528400A - - Google Patents
Info
- Publication number
- BE528400A BE528400A BE528400DA BE528400A BE 528400 A BE528400 A BE 528400A BE 528400D A BE528400D A BE 528400DA BE 528400 A BE528400 A BE 528400A
- Authority
- BE
- Belgium
- Prior art keywords
- ethylamide
- acid
- lysergic
- isolysergic
- acids
- Prior art date
Links
- CKTNHGVJKUQEBM-UHFFFAOYSA-N ethylazanide Chemical compound CC[NH-] CKTNHGVJKUQEBM-UHFFFAOYSA-N 0.000 claims description 25
- ZAGRKAFMISFKIO-QMTHXVAHSA-N lysergic acid Chemical compound C1=CC(C2=C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-QMTHXVAHSA-N 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- ZAGRKAFMISFKIO-IINYFYTJSA-N (6aR,9S)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxylic acid Chemical compound C1=CC(C2=C[C@@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-IINYFYTJSA-N 0.000 claims description 11
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 7
- VEBWTGYUIBTVNR-MLGOLLRUSA-N (6aR,9R)-N-ethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)NCC)C2)=C3C2=CNC3=C1 VEBWTGYUIBTVNR-MLGOLLRUSA-N 0.000 claims description 6
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims description 5
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 5
- 230000001624 sedative Effects 0.000 claims description 5
- 239000000932 sedative agent Substances 0.000 claims description 5
- 229940095064 tartrate Drugs 0.000 claims description 5
- VEBWTGYUIBTVNR-BLLLJJGKSA-N C(C)NC(=O)[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(C2=C1)=C34 Chemical compound C(C)NC(=O)[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(C2=C1)=C34 VEBWTGYUIBTVNR-BLLLJJGKSA-N 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- 230000001225 therapeutic Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 26
- 239000000243 solution Substances 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 6
- 230000003287 optical Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- -1 isobutyl alcohol Chemical class 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N al2o3 Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 235000011118 potassium hydroxide Nutrition 0.000 description 3
- FEWJPZIEWOKRBE-LWMBPPNESA-N (-)-tartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 2
- 241000219430 Betula pendula Species 0.000 description 2
- 210000001772 Blood Platelets Anatomy 0.000 description 2
- 229960001270 D- TARTARIC ACID Drugs 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229940023488 Pill Drugs 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 239000003518 caustics Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000003400 hallucinatory Effects 0.000 description 2
- 230000000147 hypnotic Effects 0.000 description 2
- 238000002687 lobotomy Methods 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000001184 potassium carbonate Substances 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000000698 schizophrenic Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 229960000583 Acetic Acid Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N Barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N Carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- HFFLGKNGCAIQMO-UHFFFAOYSA-N Chloral Chemical compound ClC(Cl)(Cl)C=O HFFLGKNGCAIQMO-UHFFFAOYSA-N 0.000 description 1
- 206010012357 Depersonalisation Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N Isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N Sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- CESKLHVYGRFMFP-UHFFFAOYSA-N Sulfonmethane Chemical compound CCS(=O)(=O)C(C)(C)S(=O)(=O)CC CESKLHVYGRFMFP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 229940035429 isobutyl alcohol Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003533 narcotic Effects 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 230000002441 reversible Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
Publication Number | Publication Date |
---|---|
BE528400A true BE528400A (xx) |
Family
ID=161721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE528400D BE528400A (xx) |
Country Status (1)
Country | Link |
---|---|
BE (1) | BE528400A (xx) |
-
0
- BE BE528400D patent/BE528400A/fr unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CH469659A (fr) | Procédé d'obtention de dérivés du tri-hydroxy-méthyl-aminométhane | |
CA1095520A (fr) | Procede de preparation de nouveaux derives de 20,21- dinoreburnamenine | |
EP0001733B1 (fr) | 5-Méthoxy-psoralène comme nouveau médicament et procédé de synthèse | |
HRP20090477A2 (hr) | SOL 3-BENZIL-2-METIL-2,3,3A,4,5,6,7,7A-OKTAHIDROBENZO[d]IZOKSAZOL-4-ONA | |
BE528400A (xx) | ||
BE1000157A5 (fr) | Procede de preparation de derives de la moranoline. | |
CA1140155A (fr) | PROCEDE DE PREPARATION D'UN NOUVEAU DERIVE DU 1.alpha.,25-DIHYDROXY CHOLECALCIFEROL | |
CA1186311A (fr) | Procede de preparation de nouveaux derives de 20,21- d'inoreburnamenine eventuellement substitues sur le cycle e | |
CA1185241A (fr) | [(tetra-et hexahydro pyridyl-4)-2 ethyl]-3 indoles et leur utilisation comme medicaments | |
BE1003959A5 (fr) | Agent therapeutique pour le traitement de troubles associes a l'ischemie cerebrale. | |
WO1981002295A1 (fr) | Phenoxyisobutyrates de moroxydine et medicaments les contenant | |
BE862019R (fr) | Nouveaux derives de la vincamine, leur preparation et leur application comme medicaments | |
BE521626A (xx) | ||
JPH0359063B2 (xx) | ||
CH615171A5 (xx) | ||
BE874322R (fr) | Nouveaux composes heterocycliques, leur preparation et leur application comme medicaments | |
FR2461498A1 (fr) | Procede de preparation de solutions concentrees d'amygdaline sous sa forme naturelle, et produits ainsi obtenus | |
BE636675A (xx) | ||
FR2563520A1 (fr) | Nouveaux derives d'apovincaminol, procede pour leur preparation et compositions pharmaceutiques les contenant | |
BE639292A (xx) | ||
FR2626177A1 (fr) | Nouveaux derives de l'ergoline, leur preparation et leur utilisation comme medicaments | |
CH642067A5 (fr) | Sels phosphates de la 1- et de la d,1-glaucine, leur utilisation dans des compositions pharmaceutiques et procede pour leur preparation. | |
BE738239A (xx) | ||
BE884978A (fr) | Nouveaux esters de l'acide benzoique substitue | |
CA2022594A1 (fr) | Derives d'oxazolo pyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |